Abstract Details

Title Longitudinal study of Progressive Supranuclear Palsy (PSP) using remote at-home multi-modal digital assessments and wearable devices

Topic Movement Disorders

Presentation(s) S51 - Movement Disorders: Tremor, Parkinsonism, and Non-motor Symptoms (3:42 PM-3:54 PM)

Poster/Presentation
Number 002

Objective

To measure Progressive Supranuclear Palsy (PSP) progression remotely in participants’ homes using wearable sensors, digital speech and cognitive assessments.

Background

There are limited studies using technology to objectively measure disease progression in PSP and no studies using wearable technology in participants’ homes. We hypothesized that remote, objective, quantitative measures of disease progression will facilitate clinical trials and help spur development of new therapies for PSP.

Design/Methods

Patients with clinically probable PSP by MDS 2017 criteria able to ambulate ≥10 feet unassisted were recruited at Massachusetts General Hospital and Johns Hopkins from November 2021 through September, 2022 and followed virtually monthly for 1 year.

Motor assessments performed monthly wearing LEGSys^TM and BalanSense^TM (BioSensics LLC, Newton, MA USA) devices included: balance assessments, 5x sit-to-stand, 3-meter timed up and go, and 2-minute walk tests. Participants wore PAMSys^TM (BioSensics LLC) pendant sensors for 1 year to measure physical activity, walking parameters, postural transitions, and falls during daily activities.

Digital cognitive and speech assessments performed using the BioDigit Home^TM (BioSensics LLC) tablet every 3 months included: Color Trails, Conflicting Instructions, Go/No-Go, Forward and Backward Digit Span. The PSP Rating Scale (PSPRS), MoCA, PSP-QoL and CBFS were collected virtually every 3 months or in-person.

Results

As of October 2022, 11 PSP participants were enrolled. By April 2023, 7 participants will have completed 12 months of follow-up. One participant was unable to complete virtual assessments due to lack of caregiver support and 3 participants could not perform walking tasks after 6 months.

Walking parameters, postural duration and transition times correlated strongly with disease progression as measured using the PSPRS and PSP-QoL. Instrumented gait measures correlated with activity levels.

Conclusions

Our study demonstrates the feasibility of remote longitudinal measurement of PSP progression in participants’ homes using wearable devices and digital assessments. The study identifies possible digital biomarkers of PSP progression.

Authors/Disclosures
Anne Marie A. Wills, MD (MGH) PRESENTER	Dr. Wills has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Accordant, a CVS/Caremark company. Dr. Wills has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi/Genzyme. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono Pharmaceuticals. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Wills has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Parkinson's Foundation. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx Pharmaceuticals. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ono Pharmaceuticals. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. The institution of Dr. Wills has received research support from Parkinson's Foundation. The institution of Dr. Wills has received research support from Biogen. The institution of Dr. Wills has received research support from Roche/Genentech. The institution of Dr. Wills has received research support from BioSensics.
Mansi Sharma (Massachusetts General Hospital)	Miss Sharma has nothing to disclose.
AJ Hall (Johns Hopkins University)	AJ Hall has nothing to disclose.
	No disclosure on file
Jose Joaquin Casado	No disclosure on file
Ram Kinker Mishra, PhD (Biosensics)	Dr. Mishra has received personal compensation for serving as an employee of BioSensics LLC.
Ashkan Vaziri, PhD (Biosensics LLC)	Dr. Vaziri has received personal compensation for serving as an employee of Biosensics.
Alexander Pantelyat, MD, FAAN (Johns Hopkins University School of Medicine)	Dr. Pantelyat has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for MedRhythms, Inc.. Dr. Pantelyat has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Pantelyat has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arvinas, Inc.. Dr. Pantelyat has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Dannce.ai. Dr. Pantelyat has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MedRhythms, Inc.. Dr. Pantelyat has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ono Pharma. Dr. Pantelyat has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for CurePSP. Dr. Pantelyat has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Kelly & Ignoffo Law Group. The institution of Dr. Pantelyat has received research support from NIH. The institution of Dr. Pantelyat has received research support from Department of Defense. Dr. Pantelyat has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��